Neuren Pharmaceuticals Limited (NEU.XA)
- Previous Close
11.81 - Open
11.70 - Bid --
- Ask 12.51 x --
- Day's Range
11.69 - 12.78 - 52 Week Range
8.62 - 24.00 - Volume
120,783 - Avg. Volume
129,340 - Market Cap (intraday)
-- - Beta (5Y Monthly) 1.85
- PE Ratio (TTM)
-- - EPS (TTM)
-0.07 - Earnings Date Feb 28, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide) for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid; and in Phase 2 clinical trial for the treatment of Angelman and Pitt Hopkins. In addition, it develops NNZ-2591, which is in Preclinical trial stage for the treatment of Prader-Willi syndrome. The company was incorporated in 2001 and is based in Camberwell, Australia.
www.neurenpharma.com--
Full Time Employees
December 31
Fiscal Year Ends
--
Sector
--
Industry
Recent News: NEU.XA
View MorePerformance Overview: NEU.XA
Trailing total returns as of 5/2/2025, which may include dividends or other distributions. Benchmark is MSCI WORLD (^990100-USD-STRD) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NEU.XA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NEU.XA
View MoreValuation Measures
Market Cap
--
Enterprise Value
--
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
65.51%
Return on Assets (ttm)
34.05%
Return on Equity (ttm)
49.92%
Revenue (ttm)
216.83M
Net Income Avi to Common (ttm)
142.04M
Diluted EPS (ttm)
-0.07
Balance Sheet and Cash Flow
Total Cash (mrq)
222.24M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-42.25M